LakeShore Net Income From Continuing Ops from 2010 to 2024

LSBPW Stock   0.04  0.00  0.00%   
LakeShore Biopharma Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. During the period from 2010 to 2024, LakeShore Biopharma Net Loss regression line of quarterly data had r-squared of  0.19 and coefficient of variation of (41.28). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-433.5 M
Current Value
-411.8 M
Quarterly Volatility
88.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.9 M, Interest Expense of 29.6 M or Selling General Administrative of 130.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 0.0 or Days Sales Outstanding of 304. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Check out the analysis of LakeShore Biopharma Correlation against competitors.

Latest LakeShore Biopharma's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of LakeShore Biopharma Co, over the last few years. It is LakeShore Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

LakeShore Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(213,788,578)
Coefficient Of Variation(41.28)
Mean Deviation55,690,579
Median(191,826,242)
Standard Deviation88,257,853
Sample Variance7789.4T
Range327.5M
R-Value(0.44)
Mean Square Error6787T
R-Squared0.19
Significance0.10
Slope(8,623,452)
Total Sum of Squares109052.3T

LakeShore Net Income From Continuing Ops History

2024-411.8 M
2023-433.5 M
2022-145.5 M
2021-106 M

About LakeShore Biopharma Financial Statements

LakeShore Biopharma investors use historical fundamental indicators, such as LakeShore Biopharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LakeShore Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-433.5 M-411.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LakeShore Stock Analysis

When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.